2023-503528-25-00
Completed
Phase 1
A clinical trial in healthy people to look at how the body processes RO7268489 over time and when taken before or after a meal
F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG1 site in 1 country36 target enrollmentStarted: June 1, 2023Last updated:
Overview
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG
- Enrollment
- 36
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Trial Information Support Line-TISL
Scientific
F. Hoffmann-La Roche AG
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer2022-503084-15-00Deutsches Krebsforschungszentrum (DKFZ)77
Completed
Phase 1
A study in healthy volunteers to find out how long aticaprant stays in and acts on the body when administered with or without food and with or without fluconazole2023-510472-31-00Janssen Cilag International18
Recruiting
Phase 1
A study in healthy people to test how 3 different formulations of BI 764198 are taken up in the body and how this is influenced by food2024-519615-34-00Boehringer Ingelheim International GmbH17
Completed
Phase 1
A study in healthy people to compare two different tablets of BI 685509 and to test how food and esomeprazole influence the amount of BI 685509 in the blood2023-506367-33-00Boehringer Ingelheim International GmbH16
Completed
Phase 1
A study in healthy men to test how different doses of BI 3000202 are tolerated and how food influences the amount of BI 3000202 in the blood2022-502424-43-00Boehringer Ingelheim International GmbH68